참고문헌
- Bidoli P, Zilembo N, Cortinovis D, et al (2007). Randomized phase II three-arm trial with three platinum-based doublets in metastatic non small-cell lung cancer. An Italian Trials in Medical Oncology study. Ann Oncol, 18, 461-7.
- Bulzebruck H, Bopp R, Drings P, et al (1992). New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer, 70, 1102-10. https://doi.org/10.1002/1097-0142(19920901)70:5<1102::AID-CNCR2820700514>3.0.CO;2-5
- Cardenal F, Lopez-Cabrerizo MP, Anton A, et al (1999). Randomized phase III study of gemcitabinecisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non small-cell lung cancer. JCO, 17, 12-8.
- Carr DT, Holoye PY, Hong WK (1994). Bronchogenic carcinoma. In: Murray JF, Nadel JA. Textbook of respiratory medicine. Philadelphia: WB Saunders: 2nd edition. 1528-96.
- Ciuleanu T, Brodowicz T, Zielinski C, et al (2009). Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, 374, 1432-40. https://doi.org/10.1016/S0140-6736(09)61497-5
- Crino L, Scagliotti G, Marangolo M, et al (1997). Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. JCO, 15, 297-303.
- Crino L, Weder W, Meerbeeck J van, et al (2010). Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 103-15. https://doi.org/10.1093/annonc/mdq207
- Cullen M (2005). The development of gemcitabine and carboplatin in the treatment of non small-cell lung cancer. Lung Cancer, 50, 5-7. https://doi.org/10.1016/S0169-5002(05)81550-8
- Cullen MH, Billingham LJ, Woodroffe CM, et al (1999). Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. JCO, 17, 3188-94.
- Darwish S, Minotti V, Crino L, et al (1995). A phase II trial of combined chemotherapy and surgery in stage III A non small cell lung cancer. Lung Cancer, 12, 71-8.
- Goffin J, Lacchetti C, Ellis PM, et al (2010). First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol, 5, 260-74. https://doi.org/10.1097/JTO.0b013e3181c6f035
- Gridelli C, Ardizzoni A, Douillard JY, et al (2010). Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International expert panel meeting of the Italian Association of Thoracic Oncology. Lung Cancer, 68, 319-31. https://doi.org/10.1016/j.lungcan.2009.11.018
- Han JY, Park K, Kim SW, et al (2012). First-signal: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol, 30, 1122-8. https://doi.org/10.1200/JCO.2011.36.8456
- Koo K, Zeng L, Jon F, et al (2011). Quality of life in patients treated with palliative radiotherapy for advanced lung cancer and lung metastases. World J Oncol, 2, 70-5.
- Kris MG, Natale RB, Herbst RS, et al (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 290, 2149-58. https://doi.org/10.1001/jama.290.16.2149
- Maestu I, Pastor M, Gomez-Codina J, et al (1997). Pretreatment prognostic factors for survival in small cell lung cancer: A new prognostic index and validation of three new prognostic indices on 341 patients. Ann Oncol, 8, 547-53. https://doi.org/10.1023/A:1008212826956
- Masters GA, Vokes EE (1995). Should non-small cell carcinoma of the lung be treated with chemotherapy? Pro: Chemotherapy is for non-small cell lung cancer. Am J Respir Crit Care Med, 151, 1285-7. https://doi.org/10.1164/ajrccm.151.5.7735574
- Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
- Mitsudomi T, Morita S, Yatabe Y, et al (2010). On behalf of the West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog 3405): an open label, randomised phase 3 trial. Lancet Oncol, 11, 121-8. https://doi.org/10.1016/S1470-2045(09)70364-X
- Noroxe DS, Wallerek S, Sorensen JB (2013). Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC). Anticancer Res, 33, 3275-78.
- Ostoros G, Szondy K, Gergely-Farnos E, et al (2005). Efficacy of gemcitabin . cisplatin treatment in stage III/A ("bulky" N2), IIIB and IV non small cell lung cancer. Anticancer Res, 25, 471-5.
- Pfister DG, Johnson DH, Azzoli CG, et al (2004). American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.
- Pirker R, Pereira JR, Szczesna A, et al (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 373, 1525-31. https://doi.org/10.1016/S0140-6736(09)60569-9
- Reboul F, Brewer Y, Vincent P, et al (1996). Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys, 35, 343-50. https://doi.org/10.1016/0360-3016(96)00087-9
- Rosenberg B, VanCamp L, Trosko JE, et al (1969). Platinum compounds: a new class of potent antitumour agents. Nature, 222, 385-6. https://doi.org/10.1038/222385a0
- Sandler A, Gray R, Perry MC, et al (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 355, 2542-50. https://doi.org/10.1056/NEJMoa061884
- Sandler A, Yi J, Dahlberg S, et al (2010). Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol, 5, 1416-23. https://doi.org/10.1097/JTO.0b013e3181da36f4
- Scagliotti GV, De Marinis F, Rinaldi M, et al (2002). Phase III randomized trial comparing three platinum-based doublets in advanced non small-cell lung cancer. JCO, 20, 4285-91. https://doi.org/10.1200/JCO.2002.02.068
- Scagliotti GV, Pastorino U, Vansteenkiste JF, et al (2012). Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol, 30, 172-8. https://doi.org/10.1200/JCO.2010.33.7089
- Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
- Socinski MA, Bondarenko IN, Karaseva NA, et al (2012). Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol, 30, 2055-62. https://doi.org/10.1200/JCO.2011.39.5848
- Srisam-ang K, Podhipak A, Narksawat K, et al (2005). Survival of patients with advanced non- small-cell lung cancer at ubon ratchathani cancer center, thailand. Southeast Asian J Trop Med Public Health, 36, 994-1006.
- Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (optimal, ctong-0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol, 12, 735-42. https://doi.org/10.1016/S1470-2045(11)70184-X
피인용 문헌
- Clinical Observation of Whole Brain Radiotherapy Concomitant with Targeted Therapy for Brain Metastasis in Non-small Cell Lung Cancer Patients with Chemotherapy Failure vol.14, pp.10, 2013, https://doi.org/10.7314/APJCP.2013.14.10.5699
- Efficacy of First-line Chemotherapy Affects the Second-Line Setting Response in Patients with Advanced Non-Small Cell Lung Cancer vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6799
- Clinical Study on Carboplatin for Treating Pediatric Patients with Wilms Tumors vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7277
- Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage III/IV Squamous Non-small Cell Lung Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7453
- Efficacy and Survival-associated Factors with Gefitinib Combined with Cisplatin and Gemcitabine for Advanced Non-small Cell Lung Cancer vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10967
- Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4147
- Prognostic Factors in Patients with Non-small Cell Lung Carcinoma and Brain Metastases: a Malaysian Perspective vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1901
- Association of MDR1 Gene (C3435T) Polymorphism and Gene Expression Profiling in Lung Cancer Patients Treated with Platinum-Based Chemotherapy vol.19, pp.5, 2015, https://doi.org/10.1007/s40291-015-0154-3
- Trends in incidence and associated risk factors of suicide mortality in patients with non-small cell lung cancer vol.7, pp.8, 2018, https://doi.org/10.1002/cam4.1656